Background Patients with lung cancer are at an increased risk for venous thromboembolism (VTE). Approximately 8–15% of patients with advanced non-small-cell lung cancer (NSCLC) experience a VTE throughout the course of the disease. However, the incidence of VTE in different NSCLC molecular subtypes is rarely reported, although there are significant differences in clinical feature and prognosis. Tissue factor (TF) expressed in many solid tumors could trigger the downstream coagulation cascade and lead to thrombin generation and clot formation. Results: At a median follow up of 2.5 years, 5.85% (n=30/513) patients with advanced lung adenocarcinoma experienced VTE. Compared to patients with EGFR mutation (n=11/218, 5.05%) or both negative (n=13/266, 4.89%), patients with ALK-rearrangement were more likely to develop VTE (n=6/29, 20.69%; P=0.006, P=0.004; respectively). In ALK-rearrangement-positive tissues, 41.67% (n=10/24) had a high TF protein expression; the incidence was significantly..... READ ARTICLE
Annals of Translational Medicine DOI:10.21037/atm-20-6619
Authors: Yang S, Yang L, Wu Y, Zhang C, Wang S, Ma N, Wang L, Wang
In time-to-event analyses controlling for thrombosis risk factors, the ALK rearrangement conferred a fourfold increase in VTE risk and a threefold increase in arterial thrombosis risk in NSCLC. These patients may benefit from pharmacologic thromboprophylaxis. READ ARTICLE
Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2020.04.033
Authors: Hanny Al-Samkari, Orly Leiva, Ibiayi Dagogo-Jack, Alice Shaw, Jochen Lennerz, Anthony J Iafrate, Pavan K Bendapudi, Jean M Connors
Read More